BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29446481)

  • 61. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
    Youssef MA; Abou-Setta AM; Lam WS
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD003719. PubMed ID: 27106604
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
    Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study.
    Qiu Q; Huang J; Li Y; Chen X; Lin H; Li L; Yang D; Wang W; Zhang Q
    Hum Reprod; 2020 Jun; 35(6):1411-1420. PubMed ID: 32383771
    [TBL] [Abstract][Full Text] [Related]  

  • 65. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Effect of Ovarian Stimulation on Endothelial Function-A Prospective Cohort Study using Peripheral Artery Tonometry.
    Kirshenbaum M; Haas J; Nahum R; Aizer A; Yinon Y; Orvieto R
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32968793
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy.
    Massarotti C; Stigliani S; Gazzo I; Lambertini M; Anserini P
    ESMO Open; 2023 Aug; 8(4):101597. PubMed ID: 37421801
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The number of oocytes retrieved during IVF: a balance between efficacy and safety.
    Magnusson Å; Källen K; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2018 Jan; 33(1):58-64. PubMed ID: 29136154
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL.
    Deng L; Li XL; Ye DS; Blockeel C; Zhou XY; Chen SL; Chen X
    Curr Med Sci; 2019 Apr; 39(2):278-284. PubMed ID: 31016522
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study.
    Lainas GT; Lainas TG; Sfontouris IA; Venetis CA; Bosdou JK; Chatzimeletiou A; Grimbizis GF; Tarlatzis BC; Kolibianakis EM
    Reprod Biomed Online; 2020 Jan; 40(1):168-175. PubMed ID: 31839394
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
    Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
    [TBL] [Abstract][Full Text] [Related]  

  • 73. GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis.
    Haahr T; Roque M; Esteves SC; Humaidan P
    Front Endocrinol (Lausanne); 2017; 8():116. PubMed ID: 28638367
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Symposium: Update on prediction and management of OHSS. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation.
    Kol S; Dor J
    Reprod Biomed Online; 2009 Jul; 19(1):59-60. PubMed ID: 19573291
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Moderate-to-severe ovarian hyperstimulation syndrome: A retrospective multivariate logistic regression analysis in Chinese patients.
    Ma T; Niu Y; Wei B; Xu L; Zou L; Che X; Wang X; Tang D; Huang R; Chen B
    Adv Clin Exp Med; 2020 Jan; 29(1):85-90. PubMed ID: 31990458
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C; Haahr T; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
    [TBL] [Abstract][Full Text] [Related]  

  • 77. GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study.
    Haas J; Bassil R; Samara N; Zilberberg E; Mehta C; Orvieto R; Casper RF
    Hum Reprod; 2020 Jul; 35(7):1648-1654. PubMed ID: 32563188
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Use of gonadotrophin-releasing hormone agonists to trigger ovulation.
    Tay CC
    Hum Fertil (Camb); 2002 Feb; 5(1):G35-7; discussion G38-9, G41-8. PubMed ID: 11939159
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome.
    Fusi FM; Arnoldi M; Bosisio C; Lombardo G; Ferrario M; Zanga L; Galimberti A; Capitanio E
    Gynecol Endocrinol; 2015; 31(9):693-7. PubMed ID: 26527503
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence?
    Tsoumpou I; Muglu J; Gelbaya TA; Nardo LG
    Reprod Biomed Online; 2009 Jul; 19(1):52-8. PubMed ID: 19573290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.